Clinical trials: Malignancy
Cancer
BNT001 Digital Therapeutic Feasibility Pilot Study
This single arm phase II trial focused on cancer patients and cancer survivors in the Veterans Health Administration will gather data on feasibility, acceptability, ease of clinical implementation, and preliminary efficacy of…
- Trial name
- NCT04857008
- Testing
- BNT001
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Blue Note Therapeutics
Helicobacter Pylori Infection
Evaluation of SQ109 Plus PPI in Urea Breath Test-Positive Volunteers
Helicobacter pylori infection of the gastric epithelium is the most common bacterial infection worldwide. Its global prevalence is estimated at 50%, though the burden falls disproportionately on the developing world, where the…
- Trial name
- NCT01252108
- Testing
- SQ109
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sequella, Inc.
Chronic Lymphocytic Leukemia
Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)
The primary objective of this study is to determine the preliminary efficacy of the combination of tirabrutinib (formerly GS-4059) and entospletinib with obinutuzumab in adults with relapsed or refractory chronic lymphocytic…
- Trial name
- NCT02983617
- Testing
- Tirabrutinib, Entospletinib, Obinutuzumab
- Where
- 15 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Gilead Sciences
Locally Advanced Solid Tumor, Metastatic Solid Tumor
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
This study aims to find the right dosage and evaluate the safety and effectiveness of the drug IPN60300 in adults with advanced solid tumours, which are cancers that have spread to other parts of the body from their original…
- Trial name
- NCT07213817
- Testing
- IPN60300
- Where
- 12 sites in United States, France and 1 more
- Volunteers
- 114 people
- Sponsor
- Ipsen
Gastric Cancer
Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer
Apatinib dose titration in Advanced or Metastatic Gastric Cancer
- Trial name
- NCT02764268
- Testing
- Apatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
SCLC
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with paclitaxel as second line treatment for SCLC.
- Trial name
- NCT05879068
- Testing
- PM8002, Paclitaxel
- Where
- 11 sites in China
- Volunteers
- 99 people
- Sponsor
- Biotheus Inc.
Pancreatic Cancer Non-resectable
Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer
This study is testing a new way to deliver the chemotherapy drug Gemcitabine in pancreatic tumors using the catheter Extroducer® Infusion Catheter System.
- Trial name
- NCT07575191
- Testing
- Gemcitabine, Extroducer Infusion Catheter System
- Where
- Sweden
- Volunteers
- 9 people
- Sponsor
- Smartwise Sweden AB
Sarcoma, Carcinoma
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors
20 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced solid tumors.
- Conditions
- Sarcoma, Carcinoma, Breast Cancer, Pancreatic Cancer
- Trial name
- NCT05860374
- Testing
- Recombinant oncolytic herpes simplex virus type 1 (R130)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Yunying Medical Technology
Gastrointestinal Stromal Tumors
Study for Patients Previously Treated in Avapritinib Clinical Trials
This is an open-label extension study to provide long term safety data for GIST patients who are deriving clinical benefit from avapritinib upon the completion of avapritinib clinical trials.
- Trial name
- NCT04825574
- Testing
- Avapritinib
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Blueprint Medicines Corporation
Carcinoma, Non-Small-Cell Lung
Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer
The primary Objective is to assess the efficacy of TG4010 combined to chemotherapy in comparison with chemotherapy alone in patients with advanced non small cell lung cancer.
- Trial name
- NCT00415818
- Testing
- MVA-MUC1-IL2, 1st line Chemotherapy
- Where
- 23 sites in France, Germany and 2 more
- Volunteers
- 148 people
- Sponsor
- Transgene
Advanced Cancer, Gastric Adenocarcinoma
A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
The purpose of this study is to find a recommended schedule and dose range for Emibetuzumab when given with ramucirumab that may be safely given to participants with cancer.
- Conditions
- Advanced Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Cancer
- Trial name
- NCT02082210
- Testing
- Emibetuzumab, Ramucirumab
- Where
- 4 sites in United States
- Volunteers
- 97 people
- Sponsor
- Eli Lilly and Company
Hematologic Malignancies
APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.
- Trial name
- NCT03537482
- Testing
- APG-2575
- Where
- 5 sites in United States, Australia
- Volunteers
- 90 people
- Sponsor
- Ascentage Pharma Group Inc.
Advanced Cancer
Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers
This is a Phase I study to evaluate the safety, tolerability, and efficacy of TQB2922 for injection in subjects with advanced cancers
- Trial name
- NCT06188624
- Testing
- TQB2922 for injection
- Where
- 17 sites in China
- Volunteers
- 150 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Breast Cancer, Breast Neoplasms
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
This is a phase III, double-blind, randomized, parallel-controlled, multicenter equivalence study to compare the efficacy and safety of pertuzumab biosimilar HLX11 vs.
- Conditions
- Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer
- Trial name
- NCT05346224
- Testing
- HLX11, EU-Perjeta®
- Where
- 79 sites in China, Hungary and 2 more
- Volunteers
- 900 people
- Sponsor
- Shanghai Henlius Biotech
Glioblastoma (GBM)
A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
The purpose of the study is to determine the recommended dose and further understand the safety of MT-125 in participants who have been diagnosed with glioblastoma, a primary brain tumor, when administered in combination with…
- Trial name
- STAR-GBM (NCT07185880)
- Testing
- MT-125
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Myosin Therapeutics Inc.
Infections, Papillomavirus
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. The current phase 3b study is designed to assess the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV…
- Trial name
- NCT00552279
- Testing
- Cervarix TM
- Where
- 16 sites in Italy, Romania and 1 more
- Volunteers
- 805 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Metastatic Breast Cancer
A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer
This is a multicenter, open-label, single-arm, expanded access study designed to provide T-DM1 to patients with HER2-positive locally advanced or metastatic breast cancer and to evaluate the safety and efficacy of T-DM1…
- Trial name
- NCT01120561
- Testing
- trastuzumab-MCC-DM1
- Where
- 15 sites in United States
- Sponsor
- Genentech, Inc.
Gestational Trophoblastic Neoplasia, Choriocarcinoma
Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
The purpose of the study is to determine the overall response rate of single agent TRC105 and the combination of TRC105 and bevacizumab in patients with refractory GTN (including choriocarcinoma, placental site trophoblastic…
- Conditions
- Gestational Trophoblastic Neoplasia, Choriocarcinoma, Placental Site Trophoblastic Tumor, Epithelioid Trophoblastic Tumor
- Trial name
- NCT02664961
- Testing
- TRC105, Bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Cancer
First Study of the Safety of CNTO 888 in Patients With Solid Tumors
The purpose of this study is to determine if CNTO 888 is safe and to determine how long CNTO 888 stays in the body and what effects it might have on cancer tumors.
- Trial name
- NCT00537368
- Testing
- CNTO 888
- Volunteers
- 44 people
- Sponsor
- Centocor, Inc.
Actinic Keratosis
A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis
Part 1: To identify Maximum Tolerated Dose (MTD) levels of two formulations of LEO 43204 after once daily treatment for two consecutive days Part 2: To evaluate efficacy of two formulations of LEO 43204 in two doses after once…
- Trial name
- NCT01922050
- Testing
- LEO 43204 Formulation 1, LEO 43204 Formulation 2, LEO 43204 Formulation 1 Dose X
- Where
- 25 sites in United States, Canada
- Volunteers
- 320 people
- Sponsor
- LEO Pharma